Inhibition of bcl-2 as cancer therapy

被引：33

作者：

Ciardiello, F ^{[1
]}

Tortora, G ^{[1
]}

机构：

[1] Univ Naples Federico II, Dipartimento Endocrinol & Oncol Mol & Clin, Cattedra Oncol Med, Naples, Italy

来源：

ANNALS OF ONCOLOGY | 2002年 / 13卷 / 04期

关键词：

D O I：

10.1093/annonc/mdf191

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：501 / 502

页数：2

共 21 条

[1]

Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides [J].

Agrawal, S .

BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1489 (01) :53-68

[2]

Antisense therapeutics [J].

Agrawal, S ;

Zhao, QY .

CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) :519-528

[3]

Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line [J].

Biroccio, A ;

Candiloro, A ;

Mottolese, M ;

Sapora, O ;

Albini, A ;

Zupi, G ;

Del Bufalo, D .

FASEB JOURNAL, 2000, 14 (05) :652-660

[4]

Chi KN, 2001, CLIN CANCER RES, V7, P3920

[5]

Antisense oligonucleotide inhibition of serine threonine kinases: An innovative approach to cancer treatment [J].

Cho-Chung, YS .

PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :437-449

[6]

Molecular mechanisms of antisense drugs: RNase H [J].

Crooke, ST .

ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (02) :133-134

[7]

Selected novel anticancer treatments targeting cell signaling proteins [J].

Elsayed, YA ;

Sausville, EA .

ONCOLOGIST, 2001, 6 (06) :517-537

[8]

Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO

[9]

2-D

[10]

Oligonucleotide therapeutics: A step forward [J].

Gewirtz, AM .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) :1809-1811

← 1 2 3 →